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Abstract: It is becoming increasingly clear that vitamin D has a broad range of actions in 
the human body. Besides its well-known effects on calcium/phosphate homeostasis, 
vitamin D influences muscle function, cardiovascular homeostasis, nervous function, and 
the immune response. Vitamin D deficiency/insufficiency has been associated with muscle 
weakness and a high incidence of various chronic diseases such as cardiovascular disease, 
cancer, multiple sclerosis, and type 1 and 2 diabetes. Most importantly, low vitamin D 
status has been found to be an independent predictor of all-cause mortality. Several recent 
randomized controlled trials support the assumption that vitamin D can improve muscle 
strength, glucose homeostasis, and cardiovascular risk markers. In addition, vitamin D may 
reduce cancer incidence and elevated blood pressure. Since the prevalence of vitamin D 
deficiency/insufficiency is high throughout the world, there is a need to improve vitamin D 
status in the general adult population. However, the currently recommended daily vitamin 
D intake of 5–15 µg is too low to achieve an adequate vitamin D status in individuals with 
only modest skin synthesis. Thus, there is a need to recommend a vitamin D intake that is 
effective for achieving adequate circulating 25-hydroxyvitamin D concentrations   
(>75 nmol/L). 
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1. Introduction 
Vitamin D has long been known for its effects on calcium and bone metabolism. Severe vitamin D 
deficiency causes a lack of bone mineralization, which manifests as rickets in children and 
osteomalacia in adults. There is also accumulating evidence that insufficient vitamin D status 
contributes to the bone disease osteoporosis. Adequate vitamin D supplementation can reduce the risk 
of osteoporotic fractures by approximately 20% [1]. However, it is now becoming increasingly clear 
that vitamin D has a much broader range of actions in the human body than believed before. Its 
physiological effects are not only limited to bone. Various other chronic diseases that are frequently 
observed in modern societies are probably at least in part caused by inadequate vitamin D supply. The 
present article describes the potential clinical relevance of nonclassical vitamin D actions. It refers to 
randomized, controlled clinical trials (RCTs) or meta-analyses of RCTs whenever it is possible. 
Results from non-RCTs are also presented in fields where no RCTs are available yet. Although the 
article primarily refers to the literature of the last four years, some useful older data are also included. 
Note that this article should provide evidence for nonclassical vitamin D actions. It is not a systemic 
review of the available literature. 
2. Vitamin D Metabolism  
Vitamin D is unique among vitamins in that humans can produce it themselves in their skin 
provided they have sufficient exposure to ultraviolet radiation B (290–315 nm). Vitamin D is also 
found naturally in small amounts in milk and eggs, and in relatively large amounts in fatty fish such as 
herring and mackerel. Nevertheless, skin synthesis of vitamin D usually contributes 80% to 90% to 
vitamin D supply in free-living persons. This assumption is based on the fact that in healthy young 
adults circulating 25(OH)D concentrations usually lie between 30–80 nmol/L [2], dietary vitamin D 
intake is usually below 5 µg daily [3], and 1 µg vitamin D increases circulating 25(OH)D 
concentrations by approximately 1–3 nmol/L [4,5]. The exact amount of vitamin D production in 
human skin depends on the geographic latitude, season, time of day, as well as on the weather 
conditions (cloudiness), amount of air pollution and surface reflection. In addition, clothing habits, 
lifestyle, and workplace (e.g., indoor versus outdoor), sunscreen use, and sun avoidance practices have 
a strong impact on vitamin D synthesis. It is also noteworthy that skin type determines a person’s 
effectiveness in producing vitamin D. The darker the skin is pigmented, the more ultraviolet radiation 
is absorbed by melanin and the less vitamin D is produced [6,7]. Migrant populations and their 
descendants often have skin types that do not fit to the ambient ultraviolet environment. To achieve a 
similar effect on vitamin D production compared to a fair-skinned person, the exposure time to 
ultraviolet radiation in a dark-skinned person living in Europe or North America must be up to six 
times longer [8]. 
Vitamin D can be produced very effectively by humans when ultraviolet radiation B (UVB) from 
sunlight or artificial sources reaches skin cells. A whole body exposure to UVB radiation of 15 to 20 
minutes daily is able to produce up to 250 µg vitamin D (10,000 IU) [9,10]. Once in the circulation, 
vitamin D is converted by a hepatic hydroxylase into 25-hyroxyvitamin D (25(OH)D). The circulating 
25(OH)D level is an indicator of vitamin D status. This level reflects both, ultraviolet exposure and 
dietary vitamin D intake. As needed, 25(OH)D is converted in the kidney to its active hormonal form Nutrients 2010, 2                                       
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1,25-dihydroxyvitamin D3 (calcitriol) in a process which is usually tightly controlled by parathyroid 
hormone. In spite of this, inadequate vitamin D supply lowers the circulating level of this important 
hormone [11]. Circulating calcitriol is also adversely affected by a reduced number of viable nephrons, 
high serum concentrations of fibroblast growth factor-23, and high levels of inflammatory   
cytokines [12,13].  
If vitamin D production or intake is low, vitamin D insufficiency or even deficiency is the result. 
Parathyroid hormone levels start rising at 25(OH)D cutoff levels of 75 nmol/l or lower (Table 1). The 
following cut-offs are used for different stages of vitamin D inadequacy: <25 nmol/L for deficiency  
(divide by 2.496 to convert into ng/ml), 25-49.9
  nmol/L for insufficiency, 50-74.9 nmol/L for 
hypovitaminosis/suboptimal supply. Although there is still some debate on how to classify vitamin D 
status, the vast majority of vitamin D researchers agree that 25(OH)D levels below 50 nmol/l   
are insufficient.  
Cellular vitamin D actions are mediated by a membrane-bound and a cytosolic vitamin D receptor 
(VDR). The VDR is nearly ubiquitously expressed, and almost all cells respond to vitamin D 
exposure; about 3% of the human genome is regulated, directly and/or indirectly, by the vitamin D 
endocrine system [14]. Calcitriol is also produced by local 1α-hydroxylases from its precursor 
25(OH)D in various extra-renal cells, among them vascular smooth muscle cells, colonocytes, and 
immune cells such as monocytes, dendritic cells (DCs), and B-lymphocytes [15,16]. Here, calcitriol 
plays an important paracrine and autocrine role. Uptake of 25(OH)D into extra-renal tissues is reduced 
in case of low circulating calcitriol levels, e.g., in patients with renal insufficiency [17]. 
Table 1. Vitamin D status classified according to circulating 25-hydroxyvitamin D 
concentrations [according to reference 18, with modifications according to reference 6]. 
Stage 25-hydroxyvitamin  D 
(nmol/l) 
Clinical/biochemical alterations 
Deficiency 
 
 
 
Insufficiency 
 
 
 
Hypovitaminosis D 
/suboptimal supply 
 
 
Adequacy 
 
Intoxication 
<25  
 
 
 
25 to 49.9   
 
 
 
50 to 74.9 
 
 
 
75 to 372 
 
>372 
Rickets, osteomalacia, myopathy, calcium malabsorption, 
severe hyperparathyroidism, low calcitriol concentrations, 
impaired immune and cardiac function?, death  
 
Reduced bone mineral density, impaired muscle function, 
low intestinal calcium absorption rates, elevated PTH levels, 
slightly reduced calcitriol levels 
 
Low bodily stores of vitamin D, slightly elevated PTH 
levels 
 
 
No disturbances of vitamin D-dependent functions 
 
Intestinal calcium hyperabsorption, hypercalcemia, soft 
tissue calcification, death 
Abbreviation: PTH, parathyroid hormone 
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3. Worldwide Vitamin D Status  
A recent review [19] summarized human vitamin D status according to region of the world. Six 
regions of the world were reviewed - Asia, Europe, Middle East and Africa, Latin America, North 
America, and Oceania–through a survey of published literature. Based on the articles referred to in this 
review, it was concluded that insufficient vitamin D status is prevalent in every of the six regions 
studied. Depending on the region, between 50% and more than 90% of people had 25(OH)D 
concentrations below 50 nmol/L. Low vitamin D status is most common in regions such as South Asia 
and the Middle East. Data demonstrate that insufficient vitamin D status is widespread and is re-
emerging as a major health problem globally. Urbanization in combination with modern and also 
traditional lifestyles such as indoor working, indoor leisure time activities, and traditional Islamic 
clothing, and in combination with the aging process (institutionalization) is an important risk factor for 
vitamin D insufficiency/deficiency in large parts of the adult population. In highly urbanized areas, 
individual daily sun exposure is usually too low to achieve a 25(OH)D level of 75 nmol/L. Due to the 
fact that the vast majority of foods naturally contain no or only modest amounts of vitamin D, diet is 
not able to close the gap in vitamin D supply. It is noteworthy that urbanization and industrialization 
has long been known as a major cause of childhood rickets in western countries [7]. Rickets is now on 
the increase in many developing countries, and is also re-emerging as an important health problem in 
countries with strong sun avoidance policies and cultures requiring modest dress.  
4. Diseases Associated with Nonclassical Vitamin D Actions 
Figure 1 illustrates that vitamin D deficiency/insufficiency can result in impaired musculo-skeletal 
function, impaired immune function, cardiac and vascular impairment and impaired nervous function. 
As outlined in Figure 1, the development of various chronic diseases may be the consequence. 
Figure 1. Suggested association of vitamin D deficiency/insufficiency with chronic 
diseases. 
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4.1. Vitamin D and Muscle Strengthening 
Vitamin D deficiency causes reduced aktomyosin content of myofibrils, low calcium content of 
mitochondria, reduced calcium uptake into the sarcoplasmic reticulum, and low serum levels of muscle 
enzymes [3]. The importance of vitamin D-repletion for adequate muscle function was underscored in 
a recent study in institutionalized people ≥60 years of age with insufficient vitamin D status [20]: This 
RCT demonstrated that six-month supplementation (December to May) of oral vitamin D (3,750 µg 
once a month during the first two months, followed by 2,250 µg once a month for the last four months) 
was able to improve lower limb muscle strength by 16–24%. Data support results of a recently 
performed meta-analysis of randomized controlled trials (RCTs), indicating that daily doses of 17.5 to 
20 µg supplemental vitamin D are able to prevent falls in elderly adults [21]. The relative risk of falls 
was reduced by approximately 20% if the achieved serum 25(OH)D concentrations is 60 nmol/l or 
more. In contrast to “high dose” supplemental vitamin D, low dose daily supplemental vitamin D (5 to 
15 µg) is not able to prevent falls. Thus, doses of supplemental vitamin D of less than 17.5 µg or serum 
25-hydroxyvitamin D concentrations of less than 60 nmol/L may not reduce the risk of falling among 
older individuals. It is noteworthy that in elderly people the risk of falling predicts the risk of 
developing osteoporotic fractures. Therefore, the effects of vitamin D on muscle strength may 
contribute to the preventive effect of vitamin D on osteoporotic fractures. There is also evidence that 
adequate vitamin D supply is important for muscle function in children. Already more than 50 years 
ago, Ronge [22] has demonstrated that children who have hands and face exposed to UVB radiation in 
their classroom at school for 3–5 hours during wintertime show better endurance performance 
compared to a control group without UVB exposure. Endurance performance was assessed by bicycle 
ergometry. In that study, a similar positive effect on endurance performance was seen in children who 
received a single vitamin D bolus of 6.25 mg vitamin D in February.  
4.2. Infections 
There is mounting evidence for a pivotal role of vitamin D in the immune system. Calcitriol is able 
to induce the differentiation of monocytes into macrophages. In addition, calcitriol increases the 
activity of macrophages and facilitates their cytotoxic activity. Macrophages represent the first 
unspecific defence line of the immune system. It is well known that the prevalence of infections such 
as pneumonia is high in infants with rickets [3]. The use of vitamin D (or cod liver oil) as a treatment 
of infections have been practised for over 150 years. As early as 1903, Niels Finsen was awarded the 
Nobel Prize for Medicine and Physiology for his theory to cure Lupus vulgaris (skin-tuberculosis) 
using phototherapy. In 2007, Schauber et al. [23] published data demonstrating that vitamin D is able 
to stimulate synthesis of the anti-microbial peptide cathelicidin in human skin cells to enhance innate 
immunity. A meta-analysis of observational studies has demonstrated that patients with tuberculosis 
have lower circulating 25(OH)D concentrations compared to healthy controls [24]. Ecological studies 
also support a preventive role of vitamin D in influenza: the seasonal and latitudinal distribution of 
outbreaks of influenza A in the world in 1967–1975, and weekly consultation rates for illnesses 
diagnosed clinically as influenza or influenza-like in England 1968-1970 were inversely associated 
with solar UVB radiation [25]. Very recently, it has been demonstrated in an RCT that 
supplementation with 30 µg vitamin D daily reduces the risk of wintertime influenza A in Japanese Nutrients 2010, 2                                       
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nursery school children [26]. Some epidemiological data support the assumption that vitamin D may 
reduce the susceptibility to respiratory tract infections [27,28]. In addition, vitamin D users of the 
RECORD trial [29], an RCT with approximately 3,500 participants who received 20 µg vitamin D or 
placebo, reported a lower tendency for infections and antibiotic use in March compared to vitamin D 
nonusers. In another RCT in individuals with baseline circulating concentrations below 50 nmol/L, 
supplementation with 20 µg or 50 µg vitamin D daily for three years significantly reduced upper 
respiratory tract infections compared to placebo [30]. In contrast, a daily vitamin D supplement of 50 
µg for 12 weeks did not prevent upper respiratory tract infections in individuals with baseline 
circulating 25(OH)D concentrations above 50 nmol/L [31]. Consequently, there is currently 
insufficient data to conclusively state that vitamin D supplementation could result in lowered   
infection [32]. One factor that has to be considered in future studies is baseline 25(OH)D 
concentration. In addition, the relation between vitamin D supplementation, local calcitriol, and local 
cathelicidin production has to be investigated more detailed. Interestingly, oral intake of activated 
vitamin D in rickets patients for four weeks significantly increased human cathelicidin expression in 
neutrophils compared to age-matched healthy controls without administration of activated   
vitamin D [33], indicating a critical role of adequate calcitriol availability for regulation of the innate 
immune response.   
4.3. Allergies 
Activation of the adaptive immune system is complex. Generally, it is of importance that specific 
pathways of the specific immune system are adequately suppressed in order to avoid autoimmune 
diseases or allergic reactions. Regulatory T cells are crucial for the maintenance of immunological 
tolerance. Their major role is to shut down T cell-mediated immunity toward the end of an immune 
reaction and to suppress auto-reactive T cells. A strong Th2 predominance leads to pathologic 
conditions such as overproduction of IgE and allergic diseases, whereas a strong Th1 predominance 
leads to autoimmunity and severe allograft rejection. Of clinical importance is the fact that DCs may 
induce naïve T cells in an immunogenetic direction but also in a tolerogenic direction, depending on 
the state of their maturation and their cell surface receptor. Tolerogenic DCs generally are semimature. 
There is accumulating evidence that vitamin D modulates the adaptive immune system [16]. Calcitriol 
appears to generate tolerogenic DCs in vivo, as demonstrated in models of transplantation and 
autoimmune disease. DCs appear to be key targets of calcitriol. Calcitriol arrest the differentiation and 
maturation of DCs, maintaining them in an immature state. Calcitriol is able to enhance the secretion 
by DCs of the anti-inflammatory and anti-allergic cytokine IL-10.  
At present, the vitamin D hypothesis of allergies takes two forms: Some argue that vitamin D 
deficiency may cause allergic reactions whereas others argue that vitamin D excess leads to an 
increased allergy risk. Wjst is a representative of the latter hypothesis. He argues that the increase in 
allergies in Bavaria after 1960 coincided with vitamin D supplementation intervention programs to 
prevent rickets in childhood. Moreover, both, adherence to these programs and prevalence of allergies 
in children seem to be lower in farming communities in Bavaria [34]. The farm protection is observed 
mainly during the first year of life [35], when vitamin D supplementation is also recommended. Wjst’s 
hypothesis is based on the assumption that vitamin D may lead to Th2 predominance and increased 
IgE production. Generally, his hypothesis is supported by findings that children whose mothers' Nutrients 2010, 2                                       
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concentration of 25(OH)-vitamin D in late pregnancy was >75 nmol/l had an increased risk of eczema 
on examination at nine months and asthma at age nine years compared to children whose mothers' 
concentration was <30 nmol/L [36]. In addition, vitamin D supplementation during infancy was 
associated with a higher allergy risk [37,38], and the prevalence of allergic rhinitis increased across 
quartile groups of 25(OH)D serum levels in adults of NHANES III [39].  
It is, however, noteworthy that several other epidemiological studies support the vitamin D 
deficiency hypothesis of allergic reactions [40-44]. Moreover, administration of calcitriol to blood 
cells of healthy persons and steroid-resistant asthmatic patients enhanced subsequent responsiveness to 
dexamethasone for induction of IL-10 [43]. Very few intervention trials are available so far. In a small, 
randomized, double-blind, placebo-controlled trial, vitamin D2  supplementation (25 µg/day) 
significantly improved skin symptoms in children with winter-related atopic dermatitis [45]. In a study 
in heart failure patients, vitamin D3 supplementation (50 µg/day) was able to increase blood levels of 
the anti-allergic cytokine IL-10 [46]. However, the effect on allergic reactions has not been elucidated 
in that earlier investigation.   
In total, it cannot be ruled out that vitamin D deficiency as well as vitamin D excess may increase 
the risk of allergic reactions. This assumption is supported by recent findings. Hyppönen et al. [47] 
observed a biphasic effect of vitamin D with both low and high 25(OH)D levels associated with 
elevated IgE concentrations in participants of the 1958 British birth cohort. Compared with the 
reference group with the lowest IgE concentrations [25(OH)D 100–125 nmol/L], adjusted IgE 
concentrations were 29% higher for participants with the 25(OH)D < 25 nmol/L, and 56% higher for 
participants with 25(OH)D > 135 nmol/L.  
4.4. Cancer 
Since vitamin D is a key regulator of various cellular metabolic pathways, it is important for 
cellular maturation, differentiation, and apoptosis [3]. In 2008, the WHO published a report from the 
International Agency for Research on cancer [48] that came to the conclusion that there is (i) 
consistent epidemiological evidence for an inverse association between 25(OH)D and colorectal 
cancer and colorectal adenomas, (ii) suggested epidemiological evidence for an inverse association 
between 25(OH)D and breast cancer, (iii) insufficient evidence for an inverse association between 
25(OH)D and other types of cancer, and (iv) the need for new randomized controlled trials (RCTs). 
One such RCT has already been published [49]: In a four-year, population-based study, where the 
primary outcome was fracture incidence, and the principal secondary outcome was cancer incidence, 
1179 community-dwelling women were randomly assigned to receive 1500 mg supplemental 
calcium/d alone (Ca-only), supplemental calcium plus 27.5 µg vitamin D/d (Ca + D), or placebo. 
Cancer incidence was 60–77% lower in the Ca + D women and 43% lower in the Ca-only group than 
in the placebo control subjects (P < 0.03). Gorham et al. [50] have estimated that in North America, 
Europe, and East Asia approximately 32% of  colon cancer and approximately 26% of breast cancer 
can be prevented with 50 µg vitamin D daily and 3–10 min daily of noon sunlight seasonality, when 
weather permits. Garland et al. [51] estimated that raising the minimum year-around serum 25(OH)D 
level to 100–150 nmol/L would prevent approximately 58,000 new cases of breast cancer and 49,000 
new cases of colorectal cancer each year, and three fourths of deaths from these diseases in the United 
States and Canada. Such intakes also are expected to reduce case-fatality rates of patients who have Nutrients 2010, 2                                       
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breast, colorectal, or prostate cancer by half. Nevertheless, there is also some concern that cancer risk 
is not only enhanced in individuals with deficient/insufficient vitamin D status, but also if 25(OH)D 
concentrations rise above 80 nmol/L [52], a concentration several vitamin D researchers consider 
adequate. However, this increase in cancer risk has only been observed in observational studies after 
multivariable adjustments have been made for confounding factors. This kind of exploratory data 
analysis has been criticized by some researchers [53].   
4.5. Diabetes Mellitus 
In vitro and in vivo studies suggest that vitamin D can prevent pancreatic beta-cell destruction and 
reduces the incidence of autoimmune diabetes. This may at least in part be due to a suppression of 
proinflammatory cytokines such as tumor necrosis factor (TNF)-α. Recently, the relationship between 
UVB irradiance, the primary source of circulating vitamin D in humans, and age-standardized 
incidence rates of type 1 diabetes mellitus in children aged <14 years, was analyzed according to  
51 regions of the world [54]. Incidence rates were generally higher at higher latitudes and were 
inversely associated with UVB irradiance. As early as 2001, Hyppönen et al. [55] has demonstrated in 
a birth cohort study that vitamin D supplementation was associated with a decreased frequency of type 
1 diabetes. In contrast, children suspected of having rickets during the first year of life had a three 
times higher relative risk compared with those without such a suspicion. Meanwhile, a meta-analysis 
of four case-control studies has shown that the risk of type 1 diabetes is reduced by 29% in infants who 
are supplemented with vitamin D compared to those who are not supplemented [56]. There is also 
some evidence of a dose-response effect, with those using higher amounts of vitamin D being at lower 
risk of developing type 1 diabetes. Finally, timing of supplementation might also be important for the 
subsequent development of type 1 diabetes. In a recent RCT [57], the majority of patients with latent 
autoimmune diabetes in adults increased their concentrations of plasma C–peptide levels in fasting 
state after 1 year of treatment with activated vitamin D, whereas only a minority of patients treated 
with insulin alone maintained stable fasting C-peptide levels.  
In 2007, Pittas et al. [58] conducted a systemic review and meta-analysis for observational studies 
and clinical trials in adults with outcomes related to glucose homeostasis in type 2 diabetes mellitus. 
Observational studies show a relatively consistent association between low vitamin D status and 
prevalent type 2 diabetes, with an odds ratio of 0.36 among non-Blacks for highest versus lowest  
25-hydroxyvitamin D. Evidence from RCTs with vitamin D and/or calcium supplementation suggests 
that combined vitamin D and calcium supplementation may have a role in the prevention of type 2 
diabetes only in populations at high risk (i.e,. glucose intolerance). Whereas vitamin D 
supplementation did not improve glycemic control in diabetic subjects with normal serum 25(OH)D 
levels [59], administration of 100 µg vitamin D3 improved insulin sensitivity in vitamin D deficient 
and insulin resistant South Asian women [60]. Insulin resistance was most improved when endpoint 
serum 25(OH)D reached ≥ 80 nmol/L. Optimal vitamin D concentrations for reducing insulin 
resistance were shown to be 80–119 nmol/L.  
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4.6. Cardiovascular Disease 
Globally, cardiovascular disease (CVD) is the number one cause of death. In 2005, CVD was 
responsible for approximately 30% of deaths worldwide. CVD includes various illnesses such as 
coronary heart disease (CHD), peripheral arterial disease, cerebrovascular disease such as stroke, and 
congestive heart failure. There is accumulating evidence that the vitamin D hormone calcitriol exerts 
important physiological effects in cardiomyocytes, vascular smooth muscle cells, and the vascular 
endothelium. The mechanisms have been reviewed in detail elsewhere [61]. Hypertension is a key risk 
factor for CVD. A recently published systematic review and meta-analysis came to the conclusion that 
vitamin D produces a fall in systolic blood pressure of −6.18 mm Hg and a nonsignificant fall in 
diastolic blood pressure of −2.56 mm Hg in hypertensive patients. No reduction in blood pressure is 
seen in studies examining patients who are normotensive at baseline [62]. Since these studies had 
small sample sizes, future studies should investigate their generalizability.   
Several large prospective observational or cohort studies have demonstrated that a higher vitamin D 
status is associated with approximately 50% lower cardiovascular morbidity and mortality risk 
compared with low vitamin D status (Table 2).  
Table 2. Evidence for association of circulating 25-hydroxyvitam in D level with 
cardiovascular morbidity and mortality. 
Study Design  Number  of 
individuals 
Comparator Odds/hazard  ratio  or 
Relative risk (95% CI) 
Fatal stroke 
Pilz et al. 2009 [63] 
 
Cardiovascular  
morbidity 
Wang et al. 2008 [64] 
 
Myocardial  
infarction 
Giovannucci et al. 2008 
[65] 
 
Cardiovascular 
mortality 
Dobnig et al. 2008 [66] 
 
 Pilz et al. 2009 [67] 
 
Ginde et al. 2009 [68] 
 
Prospective cohort study  
with coronary angiography 
 
 
Prospective observational 
study  
 
 
Nested case control  
study  
 
 
 
Prospective cohort study  
with coronary angiography 
 
Prospective observational study  
in  individuals 50-75 years 
 
Prospective observational study  
in individuals > 65 years. 
 
3258 
 
 
 
1739 
 
 
 
1354 
 
 
 
 
3258 
 
 
614 
 
 
3408 
 
 
Per z value of 25(OH)D  
 
 
 
25(OH)D > 37.5 nmol/L  
versus  < 25 nmol/L  
 
 
25(OH)D > 75 nmol/L  
versus < 37.5 nmol/L 
 
 
 
Median 25(OH)D 70 nmol/L  
versus 19 nmol/L 
 
Three highest versus  
lowest 25 (OH)D quartile 
 
25(OH)D > 100 nmol/L  
versus  < 25 nmol/L 
 
OR 0.58 (0.43 to 0.78) 
 
 
 
HR 0.55 (0.32 to 0.97) 
 
 
 
RR 0.48 (0.28 to 0.81) 
 
 
 
 
HR 0.45 (0.32 to 0.64) 
 
 
HR 0.19 (0.07 to 0.50) 
 
 
HR 0.42 (0.21 to 0.86) 
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The Women’s Health Initiative (WHI) calcium/vitamin D (CaD) trial could however not 
demonstrate a reduction in cardiovascular mortality by daily supplementation of 1,000 mg calcium and 
10 µg vitamin D [69]. Meanwhile it is clear that an amount of 10 µg vitamin D is far too low to result 
in a meaningful increase in serum 25(OH)D levels (see before) and that a daily calcium supplement of 
1,000 mg increases the risk for cardiovascular events in healthy older women. Both, the supplemental 
calcium in the vitamin D arm of the WHI study and the low amount of vitamin D might have 
countermanded its cardiovascular benefits. In line with this assumption, a recent meta-analysis of 
seven randomized trials showed a slight but statistically nonsignificant reduction in CVD risk (relative 
risk: 0,90; 95% CI: 0.77 to 1.05) with vitamin D supplementation at moderate to high doses 
(approximately 25µg/d) but not with calcium supplementation (relative risk: 1,14; 95% CI: 0.92 to 
1.41) or a combination of vitamin D and calcium supplementation (relative risk: 1.04; 95% CI: 0.92 to 
1.18) [70].  
In line with a potential beneficial effect of vitamin D on CVD risk, a daily vitamin D supplement of 
83 µg could improve some traditional and nontraditional cardiovascular risk markers in healthy 
overweight and obese subjects with mean 25(OH)D concentrations of 30 nmol/L who attended a 
weight-reduction program [71]. 
4.7. Multiple Sclerosis 
Multiple sclerosis (MS) is a demyellinating disease of the central nervous system that is debilitating 
and can be fatal. Manifestation of the disease is typically between the age of 20 and 40. In Europe and 
North America, regions with higher UVB radiation have low rates of MS and vice versa [3]. In Israel, 
MS prevalence depends on the country of origin. The prevalence is high in people who were born in a 
country with low UVB irradiance [72], indicating that vitamin D status during the period of early life 
is of importance for MS susceptibility. MS disease activity shows inverse fluctuations according to 
season and vitamin D status [73]. In a prospective, nested case-control study among more than seven 
million US military personnel [74], MS prevalence was lower in those people who had circulating  
25-hydroxyvitamin D concentrations between 100 and 150 nmol/L compared with those who had  
25-hydroxyvitamin D concentrations below 63 nmol/L. However, this association was only seen in 
Whites and not in Blacks, indicating that genetic factors play an important role in the pathogenesis of 
MS. Therefore, the recent finding is of importance that expression of the MS-associated MHC class II 
allele HLA-DRB1*1501 is regulated by Vitamin D [75].    
5. Mortality 
As mentioned before, vitamin D status is an important independent predictor of CVD and specific 
types of cancer. In addition, vitamin D status predicts CVD and cancer mortality. Both, CVD and 
cancer are the most important causes of mortality in developed countries. In 2007, Autier and   
Gandini [76] published a meta-analysis of randomized controlled trials (RCTs) on vitamin D and 
mortality that were not primarily designed to assess mortality. The authors found out that in middle-
aged and elderly patients with low serum concentrations of 25-hydroxyvitamin D (25(OH)D) vitamin 
D supplementation was linked to lower all-cause mortality compared to no vitamin D supplementation. Nutrients 2010, 2                                       
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Daily dose of vitamin D ranged between 10 µg and 50 µg. Risk reduction was 7% during a mean 
follow-up of 5.7 years. 
Based on the aforementioned meta-analysis, several large prospective cohort studies were recently 
published on all-cause mortality and vitamin D status (Table 3). They demonstrate a consistent 
increase in mortality risk in patients with insufficient or deficient 25(OH)D concentrations. However, 
low 25(OH)D was not an independent predictor for mortality in patients with advanced   
disease [77,78]. One may speculate that in this case, vitamin D supplementation is unable to reverse 
the already existing severe pathophysiologic derangements.   
Table 3. Evidence for association of circulating 25-hydroxyvitamin D level or vitamin D 
supplementation with all-cause mortality. 
Study Design  Number  of 
individuals 
Comparator  Hazard ratio or 
relative risk (95% CI) 
Autier and  
Gandini, 2007 
[76] 
 
Dobnig et al. 
 2008 [66] 
 
Kuroda et al.  
2009 [77] 
 
Ng et al.  
2008 [78]
 
 
Ginde et al.  
2009 [68] 
 
Pilz et al.  
2009 [67] 
Meta-analysis of 18 vitamin D  
supplementation studies 
 
Prospective cohort study with  
coronary angiography 
 
Prospective observational study  
in postmenopausal women 
 
Prospective cohort study in  
patients with colorectal cancer 
 
Prospective observational study 
in individuals > 65 years. 
 
Prospective observational study  
In individuals 50-75 years 
57,311 
 
 
3,258 
 
 
1,232 
 
 
304 
 
 
3,408 
 
 
614 
Supplemented  
versus unsupplemented  
 
Median 25(OH)D 70 
nmol/L versus 19 nmol/L 
 
≥ 50 nmol/L  
versus  < 50 nmol/L 
 
Mean 41 nmol/L  
versus 100 nmol/L 
 
25(OH)D > 100 nmol/L  
versus < 25 nmol/L 
 
Three highest quartiles  
versus lowest quartile 
RR 0.93 (0.87 to 0.99) 
 
 
HR 0.48 (0.37 to 0.63) 
 
 
HR 0.46 (0.27 to 0.79) 
 
 
HR 0.52 (0.29 to 0.94) 
 
 
HR 0.55 (0.34to 0.88) 
 
 
HR 0.51 (0.28 to 0.93) 
 
6. Conclusions 
In 2003, a review article had summarized the association of insufficient vitamin D status with 
various diseases such as myopathy, CVD, cancer, diabetes mellitus, MS, and infections [8]. 
Meanwhile, evidence has accumulated that vitamin D may indeed play an important role in the 
etiology of many of these diseases. Meta-analyses of RCTs demonstrate that vitamin D improves 
muscle function and seems to reduce blood pressure in hypertensive patients. In addition, some RCTs 
demonstrate that vitamin D reduces cancer incidence, and improves glucose homeostasis in patients 
with type 2 diabetes and cardiovascular risk markers in overweight people [49,60,71]. The most 
exiting result is however the fact that vitamin D may reduce mortality rate. This latter finding fits well 
together with the fact that severe deficiency of several other vitamins such as retinol, thiamine, niacin, 
and ascorbic acid is also associated with enhanced mortality. Nevertheless, additional large RCTs are 
needed to confirm whether or not vitamin D is able prolong survival in individuals with inadequate 
vitamin D status. In this context, the effect of vitamin D in deficient and insufficient individuals should 
be investigated separately.  
Some aforementioned beneficial data on glucose homeostasis and cardiovascular risk markers were 
not confirmed by recent RCTs [59,81]. All these RCTs performed so far were relative small in sample Nutrients 2010, 2                                       
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seize [59,60,71,81]. In addition, individual medication and baseline circulating 25(OH)D 
concentrations may have influenced study results. Therefore, additional research is necessary to clarify 
whether or not vitamin D supplementation is indeed effective in secondary prevention and also in 
tertiary prevention of chronic diseases. But we should be aware of the fact that many chronic diseases 
are of multi-factorial origin. Vitamin D is certainly only one factor among others. In addition, there 
may be individual differences with respect to the metabolic pathways that are disturbed in vitamin D 
deficient persons. Therefore, we should not be too enthusiastic that future RCTs will show clear 
beneficial vitamin D effects. For example, the meta-analysis by Autier and Gandini was based on more 
than 55,000 individuals. None of the single studies included in this analysis showed a significant 
vitamin D effect on mortality, indicating that huge sample seizes are probably needed to demonstrate a 
clear vitamin D effect. Even so, the consequences on a population scale may be important because of 
the large number of people who are affected.  
The effect of vitamin D on MS, type 1 diabetes, infections, and allergies is less clear at present. 
Although newborns usually receive vitamin D supplements for preventing rickets, possible adverse 
effects of deficient vitamin D concentrations during fetal development such as increased susceptibility 
for type I diabetes and MS have to be considered as well. It is noteworthy that many women of 
childbearing age worldwide are vitamin D insufficient or even deficient [19,82]. With respect to MS, 
type 1 diabetes, and allergies, more birth cohort studies are needed.  
Despite some uncertainties with respect to vitamin D and health, there is general agreement that 
currently a high percentage of people worldwide have low vitamin D status [19,83]. The recommended 
daily vitamin D intake of 5–15 µg is too low to achieve an adequate vitamin D status in people with 
only modest UVB exposure. Generally, treating vitamin D deficiency is easy to perform, safe, and 
inexpensive. Sources of vitamin D could include a combination of food fortification, supplements, and 
natural and artificial UV-B irradiation, if properly acquired. It has been calculated that 1 µg vitamin D 
increases circulating 25(OH)D levels by approximately 1 nmol/L [4]. Thus, a daily intake of 
approximately 50 µg vitamin D would be necessary for increasing the circulating 25(OH)D level from 
25 nmol/L to 75 nmol/L. In order to achieve a 25(OH)D concentration above 75 nmol/L in almost all 
individuals of a group with mean baseline 25(OH)D concentrations of 38 nmol/L, daily 
supplementation with up to 100 µg vitamin D is necessary [5]. In otherwise healthy adults, the risk of 
vitamin D intoxication is extremely rare [3,84]. Vitamin D intoxications such as hypercalcemia do not 
occur until oral vitamin D intake and serum 25(OH)D concentrations exceed 250 µg/day 
(approximately 3–5 µg/kg body weight) [84] and 372 nmol/L [6], respectively. A daily amount of up 
to 250 µg vitamin D is similar to the amount that is produced by daily whole body exposure to UVB 
radiation [10].  
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